A Randomized Double-Blinded Study of V-502 Administered to 16- to 26- Year-Old Women.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2014
At a glance
- Drugs Human papillomavirus vaccine recombinant octavalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections; Vulvovaginal cancer
- Focus Therapeutic Use
- Sponsors Merck & Co
- 09 Jan 2007 Status change
- 05 Nov 2006 New trial record.